BioSpace News Archive

Bio-Techne Corporation announced it has completed its investment in Wilson Wolf Manufacturing.

BioNTech SE and Duality Biologics Co. Ltd. announced that the companies have entered into exclusive license and collaboration agreements for two ADC assets to develop, manufacture and commercialize the two assets globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.

Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating VO659 for the treatment of Huntington’s disease (HD), spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3).

Context Therapeutics Inc., a biopharmaceutical company developing novel treatments for solid tumors, announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2023.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer, effective March 31.

OpGen, Inc. reported that it has completed two interim milestones as part of its collaboration project with InfectoGnostics under the PREPLEX grant.

Cyclerion Therapeutics, Inc. announced that the Board of Directors of the Company, acting solely by all of its independent and disinterested members, has reviewed a non-binding proposal received on March 17, 2023 from an entity formed by investors that include the Company’s Chief Executive Officer, to purchase the Company’s zagociguat and CY3018 assets.

Kodiak Sciences Inc. (Nasdaq: KOD) announced today that the first patient has been treated in the Phase 1 study of KSI-501, an investigational bispecific antibody biopolymer conjugate targeting both VEGF and IL-6. KSI-501 is the second product candidate built on Kodiak’s Antibody Biopolymer Conjugate (ABC) Platform to enter the clinic.

Alimera Sciences, Inc. announces that it has further expanded its relationship with Horus Pharma, one of the Company’s current distributors of ILUVIEN® in Europe.

Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported topline results from its Phase 2 clinical trial evaluating pomotrelvir for the treatment of mild-to-moderate COVID-19 in test-positive, symptomatic, otherwise healthy, vaccinated adults without risk factors for developing severe disease.